Camlin Fine Sciences Limited (CAMLINFINE)

Loading page…

Camlin Fine Sciences Limited (CAMLINFINE) · mywealthgrid

About

Camlin Fine Sciences is a specialty chemicals company operating in the Materials sector with a market cap of ₹1,993 Cr. The company operates at scale—consolidated revenues in the range of ₹425–₹520 Cr per quarter—with both standalone operations and group subsidiaries. Specialty chemicals positions the company in a higher-value segment of the chemicals industry, though recent quarters show operational stress across both dimensions.

Founded: 1931
Face value: ₹1

Market cap

₹1,748 Cr

P/E

297.3×

P/B

1.7×

Dividend yield

ROE

2.8%

ROCE

5.1%

Debt / equity

0.64

OPM

6.2%

EPS (TTM)

₹0.3

Book value

₹54.2

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Net losses persisting across standalone operations (−₹12.31 Cr Jun 2026, −₹5.65 Cr Mar 2026) and extending into consolidated results (−₹33.62 Cr Jun 2026) suggest widespread operational distress
Operating margins collapsed from 8.67% in Dec 2025 to 1.79% in Jun 2026—a 75% drop in one quarter; verify whether this is temporary disruption or structural deterioration
Stock declined 57.57% over one year (from ₹238.1 to ₹103.76 current), indicating sustained investor loss of confidence; verify if company-specific or sector-wide downturn
ROE of 2.84% signals minimal capital efficiency; weak earnings combined with D/E of 0.64 means growing losses could trigger covenant issues or forced capital raises

Generated analysis · source review pending

Growth drivers

Consolidated revenue of ₹519.88 Cr in Jun 2026 is 2.3x standalone ₹222.49 Cr, indicating material group operations that could be leveraged; verify if subsidiaries are accretive and opportunities to scale them
Mar 2026 consolidated profit of ₹86.28 Cr despite ₹5.65 Cr standalone loss shows group subsidiaries contributed profitably; confirm if this has continued into recent quarters
Operating margin fell from 8.67% (Dec 2025) to 1.79% (Jun 2026); if this is cyclical disruption rather than structural, recovery to mid-range margins on current ₹500 Cr revenue base would significantly improve earnings
Specialty chemicals positioning in Materials sector may offer insulation from commodity pressures; verify the company's specific end-markets, competitive position, and demand trends

Generated analysis · source review pending

2,528 historical price candles were omitted because the exchange source has not been verified.

₹91.0-2.3%1Y

Quick read

rule-based

Pros

No positive flags triggered.

Cons

−Low return on equity of -8% (3-yr avg)
−Thin operating margin of 6.2%
−Profit declined 11.5% a year over the last 5 years
−Modest revenue growth of 7.7% a year over the last 5 years
−Weak interest coverage of 0.9×
−Expensive at 297.3× trailing earnings

Research score

Structured signal from quality, growth, valuation and momentum.

25/100

Business quality: 14
Growth: 32
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	723	892	1,049	1,187	1,412	1,682	1,613	1,667	1,723
COGS	422	475	534	583	759	813	914	849	922
Gross profit	300	417	515	604	653	868	699	817	801
	288	349	385	422	500	663	626	609	692
	13	69	131	182	153	205	74	209	109
OPM %	1.7%	7.7%	12.5%	15.3%	10.8%	12.2%	4.6%	12.5%	6.3%
Depreciation	27	29	33	44	56	63	79	64	71
Interest	28	37	43	38	36	59	60	100	73
	12	14	3	5	33	-4	-34	-203	58
Profit before tax	-31	17	58	105	94	80	-99	-158	23
Tax	-7	14	28	40	34	41	6	0	-0
Tax %	-22%	82%	48.8%	37.8%	35.8%	50.5%	5.7%	0%	-2%
	-24	3	30	65	60	40	-105	-158	24
PAT margin %	-3.3%	0.3%	2.8%	5.5%	4.3%	2.4%	-6.5%	-9.5%	1.4%
EPS (₹)	-3.1	0.1	2.5	4.1	4.7	3.5	-5.6	-8	1.5
EPS adjusted (₹)	-2.5	0.1	2.5	4	3.9	3.3	-5.5	-7.4	1.4
Annual report	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	10	12	12	12	13	16	16	17	19	19
Reserves	171	359	359	391	631	732	804	848	883	1,022
Minority interest	—	62	59	57	70	17	5	—	—	—
	252	357	438	490	538	623	780	658	646	668
	133	226	219	284	231	412	456	429	476	615
Total equity & liabilities	567	1,017	1,087	1,234	1,482	1,800	2,060	1,952	2,024	2,324
	176	276	270	270	550	557	858	816	702	887
CWIP	25	13	57	176	24	215	41	46	10	33
Investments	13	115	11	7	7	7	8	8	63	30
	353	612	749	781	900	1,021	1,154	1,082	1,249	1,373
Total assets	567	1,017	1,087	1,234	1,482	1,800	2,060	1,952	2,024	2,324

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	46.8%	49.1%	50.8%	46.2%	51.6%	43.4%	49%	46.5%
EBITDA margin %	7.7%	12.5%	15.3%	10.8%	12.2%	4.6%	12.5%	6.2%
EBIT margin %	4.4%	9.3%	11.6%	6.9%	8.5%	-0.3%	8.7%	2.1%
PAT margin %	0.3%	2.8%	5.5%	4.3%	2.4%	-6.5%	-9.5%	1.4%
Working capital
Receivable days	86	88	83	77	66	65	72	79
Inventory days	219	204	200	178	255	205	226	199
Payable days	3	6	99	2	129	130	162	200
NWC days	302	286	184	254	192	140	136	78
Leverage
Current ratio	1.46	1.23	1.66	1.5	1.37	1.36	1.4	1.27
Debt to EBITDA	6.38	3.75	2.96	4.08	3.8	8.9	3.1	6.25
Debt to equity	1.18	1.21	0.84	0.83	0.95	0.76	0.72	0.64
Interest coverage	1.5	2.3	3.8	3.6	2.5	0.2	1.6	0.9
Asset turnover	0.82	0.85	0.8	0.78	0.82	0.83	0.82	0.74
Return ratios
Return on assets %	0.3%	2.4%	4.4%	3.4%	1.9%	-5.4%	-7.8%	1%
Return on capital employed %	9.1%	15.4%	16.9%	11.8%	12%	0.9%	13.2%	5.1%
Return on equity %	0.8%	7.4%	10.2%	8.1%	4.9%	-12.1%	-17.5%	2.3%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	48.03%	48.03%	48.03%	48.02%	48.02%	48.02%	49.1%	49.1%	49.08%	48.03%	48.03%	48.03%
	1.61%	0.99%	1.69%	1.01%	0.81%	0.76%	1.47%	2.88%	2.12%	2.12%	0.94%	0.91%
	3.9%	3.75%	4.54%	4.89%	4.24%	3.39%	3.83%	4.14%	5.48%	7.77%	7.7%	5.42%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	46.46%	47.23%	45.74%	46.08%	46.93%	47.83%	45.6%	43.88%	43.32%	42.08%	43.33%	45.64%
No. of shareholders	—	—	—	—	—	—	—	—	57,661	52,357	52,232	55,178

Promoter holding up 0 percentage points since Sep 2023.

1 disclosure

Person	Deal	Shares	Value	Holding	Filed
Arjun DukaneDirector	BuyESOP	10,000	₹8.5 L	0.00% → 0.00%	17 Sept 20257(2)

Disclosed under SEBI’s insider-trading regulations, which require a filing only above ₹10 lakh in a quarter — smaller dealings are in no disclosure. Holdings are the filer’s own percentages, not recomputed.

20 deals · 5 Apr 2024 – 23 Apr 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
23 Apr 2026	JUNOMONETA FINSOL PRIVATE LIMITED	Bulk	NSE	Buy	11,68,988	₹119.80	₹14.00 Cr
23 Apr 2026	JUNOMONETA FINSOL PRIVATE LIMITED	Bulk	NSE	Sell	11,58,385	₹119.87	₹13.89 Cr
29 Sept 2025	AKSHAT GREENTECH PRIVATE LIMITED	Bulk	NSE	Buy	10,00,000	₹200.08	₹20.01 Cr
27 May 2025	ADITYA SINGHANIA	Bulk	NSE	Buy	10,47,106	₹244.58	₹25.61 Cr
1 Jan 2025	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Buy	8,68,862	₹140.65	₹12.22 Cr
1 Jan 2025	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Sell	8,68,862	₹140.58	₹12.21 Cr
4 Sept 2024	INFINITY PORTFOLIO HOLDINGS	Block	NSE	Buy	13,38,600	₹102.98	₹13.78 Cr
4 Sept 2024	INFINITY DIRECT HOLDINGS	Block	NSE	Sell	13,38,600	₹102.98	₹13.78 Cr
4 Sept 2024	INFINITY PORTFOLIO HOLDINGS	Bulk	NSE	Buy	13,38,600	₹102.98	₹13.78 Cr
4 Sept 2024	INFINITY DIRECT HOLDINGS	Bulk	NSE	Sell	13,38,600	₹102.98	₹13.78 Cr

1–10 of 20

1 / 2

Mr. Ashish Subhash DandekarExecutive Director-Chairperson related to Promoter-MD
Ms. Anagha Subhash DandekarNon-Executive - Non Independent Director
Mr. Nirmal Vinod MomayaExecutive Director-MD
Mr. Arjun Sudhakar DukaneExecutive Director
Mr. Amol Jashvant ShahNon-Executive - Independent Director
Mr. Harsha RaghavanNon-Executive - Non Independent Director
Mr. Josephconrad Agnelo DsouzaNon-Executive - Independent Director
Mr. M G PalekarNon-Executive - Independent Director
Mr. Pradip Manilal KanakiaNon-Executive - Independent Director
Mr. Abeezar E FaizullabhoyNon-Executive - Independent Director
Mr. Jens Van NieuwenborghNon-Executive - Non Independent Director

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 2 fund houses

Held by these funds

4.97%

of the company's equity

All mutual funds

5.12%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

4 schemes · 2 fund houses

		Shares
Commodities Fund	ICICI Prudential Mutual Fund	60.93 L	62.54	1.46%	3.172%	-0
Multi Cap FundNEW	ICICI Prudential Mutual Fund	33.66 L	34.54	0.18%	1.752%	—
Mid Cap FundNEW	ICICI Prudential Mutual Fund	82,527	0.85	0.01%	0.043%	—
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	268	0	0%	0%	-0

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

20 announcementsExport CSV

16 Sept 2026, 4:52 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

15 Sept 2026, 11:28 amAGM/EGM

Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

Postal Ballot PDF

9 Sept 2026, 3:39 pmCompany Update

Announcement under Regulation 30 (LODR)-Change in Management

Change in Management PDF

17 Aug 2026, 6:40 pmCompany Update

Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Earnings Call Transcript PDF

11 Aug 2026, 6:53 pmCompany Update

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Analyst / Investor Meet PDF

11 Aug 2026, 4:40 pmCompany Update

Announcement under Regulation 30 (LODR)-Investor Presentation

Investor Presentation PDF

11 Aug 2026, 4:15 pmBoard Meeting

Board Meeting Outcome for Outcome Of Board Meeting Dated August 11, 2026

Outcome of Board Meeting PDF

11 Aug 2026, 4:13 pmResult

Un-Audited Financial Results For The Quarter Ended June 30, 2026

Financial Results PDF

Date	Category	Subject	Filing
16 Sept 2026, 4:52 pm	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF
15 Sept 2026, 11:28 am	AGM/EGM Postal Ballot	Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	46.8%	49.1%	50.8%	46.2%	51.6%	43.4%	49%	46.5%
EBITDA margin %	7.7%	12.5%	15.3%	10.8%	12.2%	4.6%	12.5%	6.2%
EBIT margin %	4.4%	9.3%	11.6%	6.9%	8.5%	-0.3%	8.7%	2.1%
PAT margin %	0.3%	2.8%	5.5%	4.3%	2.4%	-6.5%	-9.5%	1.4%
Working capital
Receivable days	86	88	83	77	66	65	72	79
Inventory days	219	204	200	178	255	205	226	199
Payable days	3	6	99	2	129	130	162	200
NWC days	302	286	184	254	192	140	136	78
Leverage
Current ratio	1.46	1.23	1.66	1.5	1.37	1.36	1.4	1.27
Debt to EBITDA	6.38	3.75	2.96	4.08	3.8	8.9	3.1	6.25
Debt to equity	1.18	1.21	0.84	0.83	0.95	0.76	0.72	0.64
Interest coverage	1.5	2.3	3.8	3.6	2.5	0.2	1.6	0.9
Asset turnover	0.82	0.85	0.8	0.78	0.82	0.83	0.82	0.74
Return ratios
Return on assets %	0.3%	2.4%	4.4%	3.4%	1.9%	-5.4%	-7.8%	1%
Return on capital employed %	9.1%	15.4%	16.9%	11.8%	12%	0.9%	13.2%	5.1%
Return on equity %	0.8%	7.4%	10.2%	8.1%	4.9%	-12.1%	-17.5%	2.3%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Gujarat Fluorochemicals LimitedFLUOROCHEMFLUOROCHEM	₹47,713 Cr	₹49,912 Cr	₹5,303 Cr	₹1,375 Cr	25.8%	₹615 Cr	11.5%	11.1%	7.6%	401
Navin Fluorine International LimitedNAVINFLUORNAVINFLUOR	₹41,740 Cr	₹42,967 Cr	₹3,634 Cr	₹1,232 Cr	32.6%	₹790 Cr	20%	21.6%	20.1%	61
Aether Industries LimitedAETHERAETHER	₹22,161 Cr	₹22,603 Cr	₹1,224 Cr	₹384 Cr	31.3%	₹235 Cr	19.8%	13.2%	9.4%	330
Atul LimitedATULATUL	₹17,231 Cr	₹17,411 Cr	₹6,643 Cr	₹1,189 Cr	16.4%	₹704 Cr	11%	14.1%	11.5%	70
Aarti Industries LimitedAARTIINDAARTIIND	₹16,869 Cr	₹21,790 Cr	₹9,012 Cr	₹1,337 Cr	14.1%	₹531 Cr	5.1%	8.8%	7.3%	54
Fine Organic Industries LimitedFINEORGFINEORG	₹15,752 Cr	₹15,797 Cr	₹2,472 Cr	₹535 Cr	20.4%	₹438 Cr	17.6%	21.6%	16.8%	113
Basf India LimitedBASFBASF	₹14,796 Cr	₹14,796 Cr	₹16,177 Cr	₹952 Cr	4.4%	₹643 Cr	2.8%	14%	11.1%	40
Privi Speciality Chemicals LimitedPRIVISCLPRIVISCL	₹13,970 Cr	₹14,980 Cr	₹2,671 Cr	₹666 Cr	25.2%	₹342 Cr	12.4%	27.7%	25.2%	158
Sudeep Pharma LimitedSUDEEPPHRMSUDEEPPHRM	₹13,546 Cr	₹13,694 Cr	₹676 Cr	₹233 Cr	34.6%	₹133 Cr	27.1%	31.1%	25.2%	366
Anupam Rasayan India LimitedANURASANURAS	₹13,243 Cr	₹15,058 Cr	₹2,535 Cr	₹563 Cr	22.2%	₹175 Cr	9.4%	9.1%	5.5%	377
Vinati Organics LimitedVINATIORGAVINATIORGA	₹12,528 Cr	₹12,528 Cr	₹2,381 Cr	₹665 Cr	29.4%	₹448 Cr	19.9%	18.8%	14.9%	152
Elantas Beck India LimitedELANTASELANTAS	₹10,644 Cr	₹10,644 Cr	₹778 Cr	₹147 Cr	20.3%	₹136 Cr	17.4%	20.6%	15.8%	70

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-9	-15	-9	86	117	145	51	139	27	82
	-83	-149	-2	-90	-133	-249	-125	-67	-75	-53
	91	182	26	3	39	136	60	-86	72	-25
Net cash flow	-1	18	15	-1	23	32	-14	-13	24	4
Free cash flow	-39	-35	-78	-48	34	-68	-93	78	-16	25
CFO / Operating profit %	—	-122.9%	-13.1%	65.8%	64.5%	95.2%	24.8%	188%	12.8%	76.8%

Camlin Fine Sciences Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Events

Announcements

Not in the F&O segment

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

9

1

2

Compounded sales growth

Compounded profit growth

Return on equity

Camlin Fine Sciences Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Insider dealing

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Events

Announcements

Ratio timeline

Not in the F&O segment

Quarterly record

Insider dealing

Bulk & block deals

Board and management

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Dividends9

Board meetings1

Stock splits2

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

9

1

2